Navigation Links
Angiotech wins before the UK House of Lords
Date:7/10/2008

such forward-looking statements. Page 1 of 2 Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the deve
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Today the National Institutes ... grants for the Brain Research through Advancing Innovative ... develop and revolutionize new methods of understanding the ... brain. This first round of grants totaling $46 ... allocated to more than 100 investigators in 15 ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
Breaking Biology Technology:NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2
... UBS Global Life Sciences ... Conference, ... technology that accelerates the development,of life science and pharmaceutical products, today announced ... a top global,healthcare investment firm. MPM Capital also participated as a new ...
... 23 Arisyn Therapeutics Inc.,(Arisyn) announced today day ... Research, L.L.C. (UTR) a series of highly novel ... a variety of infectious organisms and cancer. Under ... intellectual property portfolio. In,return, UTR will receive a ...
... Global Certified Advantage Partnership streamlines management of patient ... data collected during ... Computer,Services Ltd. (NYSE: SAY ), a leading global ... working with Oracle,s,new Health Sciences Global Business Unit to ...
Cached Biology Technology:ForteBio, Inc. Closes $25 Million In Series C Financing 2ForteBio, Inc. Closes $25 Million In Series C Financing 3Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer 2Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer 3Satyam Partners with Oracle to Provide Clinical Development Applications 2Satyam Partners with Oracle to Provide Clinical Development Applications 3Satyam Partners with Oracle to Provide Clinical Development Applications 4
(Date:9/30/2014)... tourists visit the Mediterranean each year, but its ... on Earth. Almost 1,000 alien species, including fish, ... seas through human activities. In the open-access journal ... team of researchers analyzed data from a new ... show how the introduction of alien species has ...
(Date:9/30/2014)... San Diego, have completed the first comprehensive numerical simulation ... the pixels in an image as data points for ... The researchers, led by J.S. Chen, the William Prager ... Engineering at UC San Diego, presented their findings on ... in Pittsburgh this month. Chen also gave a keynote ...
(Date:9/30/2014)... by the Ocean Health Index rates the Earth,s ... health. In addition, for the first time, the ... regions beyond national jurisdiction (high-seas areas) all ... biodiversity and providing sustainable food sources. , In ... partnership led by scientists from UC Santa Barbara,s ...
Breaking Biology News(10 mins):Biodiversity in the Mediterranean is threatened by alien species 2First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Rating the planet's oceans 2Rating the planet's oceans 3
... Since Moffat and Ramsden for the first time discovered ... 1977, over the last two decades, great progress has ... Jrgensen and Mathiesen were the first authors to note ... in adult Australian parrots. Later, Roberson et al studied ...
...  DiscoveRx Corporation, through its BioSeek division, today announced ... assay platform for oncology research. Consisting of primary ... panel enables researchers to easily assess the phenotypic ... to better predict in vivo drug ...
... plants, the growth of organs such as roots, leaves ... reservoir-like compartments hold stem cells, which have the ability ... At Cold Spring Harbor Laboratory (CSHL), Professor David ... insights about how plants regulate their growth. This work ...
Cached Biology News:DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research 2DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research 3In odd-looking mutant, clues about how maize plants control stem cell number 2
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Mouse monoclonal antibody to RNase L...
Anti (porcine) Vitronectin...
Biology Products: